Literature DB >> 27436464

Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated from community-acquired respiratory tract infections in China: Results from the CARTIPS Antimicrobial Surveillance Program.

Yawei Zhang1, Feifei Zhang1, Hui Wang2, Chunjiang Zhao1, Zhanwei Wang1, Bin Cao3, Yan Du4, Xianju Feng5, Yunjian Hu6, Bijie Hu7, Ping Ji8, Zhiyong Liu9, Yong Liu10, Wanzhen Liao11, Juan Lu12, Hongli Sun13, Zhongxin Wang14, Xiuli Xu15, Xuesong Xu16, Qing Yang17, Yunsong Yu18, Rong Zhang19, Chao Zhuo20.   

Abstract

This study investigated the antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolates causing adult community-acquired respiratory tract infections (CARTIs) in China. A multicentre resistance surveillance study (CARTIPS) investigating 1046 clinical isolates from 19 hospitals in China was conducted from 2013 to 2014. Based on the minimum inhibitory concentration (MIC) breakpoints of oral penicillin, the percentages of penicillin-resistant, penicillin-intermediate and penicillin-susceptible S. pneumoniae were 44.1%, 13.7%, and 42.2%, respectively. The rates of penicillin-non-susceptible S. pneumoniae ranged from 27.9% to 72.2% in different cities, with the highest rate in Nanchang. Macrolides, including azithromycin, clarithromycin and erythromycin, showed the lowest activities against S. pneumoniae isolates, with resistance rates of 90.5%, 92.2% and 93.0%, respectively. However, 98% of these strains were susceptible to levofloxacin and moxifloxacin. For H. influenzae isolates, most of the antimicrobials agents exhibited good activities. However, ampicillin and trimethoprim/sulfamethoxazole showed relatively lower activity against H. influenzae, with resistance rates of 35.0% and 54.4%, respectively. β-lactamase production rates amongst H. influenzae and M. catarrhalis were 31.0% and 87.1%, respectively. In addition, a total of 15 β-lactamase-negative ampicillin-resistant (BLNAR) strains identified in this study were resistant to ampicillin, amoxicillin/clavulanic acid, cefaclor and cefuroxime. Most of the antimicrobial agents showed excellent activity against M. catarrhalis, with susceptibility rates of >90%. The results from the current study confirmed the regional variations in antimicrobial susceptibility of major CARTI pathogens and provided some choices for the treatment of these organisms. Continuous national surveillance of the epidemiology of CARTIs is strongly warranted in China.
Copyright © 2016 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antimicrobial resistance; Community-acquired respiratory tract infection; Surveillance

Mesh:

Substances:

Year:  2016        PMID: 27436464     DOI: 10.1016/j.jgar.2016.03.002

Source DB:  PubMed          Journal:  J Glob Antimicrob Resist        ISSN: 2213-7165            Impact factor:   4.035


  11 in total

1.  Carbapenem-Nonsusceptible Haemophilus influenzae with Penicillin-Binding Protein 3 Containing an Amino Acid Insertion.

Authors:  Kazuki Kitaoka; Kouji Kimura; Hiromitsu Kitanaka; Hirotsugu Banno; Wanchun Jin; Jun-Ichi Wachino; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

2.  Metagenomic next-generation sequencing for the detection of pathogenic microorganisms in patients with pulmonary infection.

Authors:  Peng Wei; Lijuan Wu; Yu Li; Jian'gang Shi; Yifeng Luo; Wenbin Wu; Jiemei Feng
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

3.  Antimicrobial susceptibility among Streptococcus pneumoniae and Haemophilus influenzae collected globally between 2015 and 2017 as part of the Tigecycline Evaluation and Surveillance Trial (TEST).

Authors:  Zhijie Zhang; Meng Chen; Ying Yu; Sisi Pan; Yong Liu
Journal:  Infect Drug Resist       Date:  2019-05-10       Impact factor: 4.003

4.  Clinical And Bacteriological Impact Of Clarithromycin In Streptococcal Pharyngitis: Findings From A Meta-Analysis Of Clinical Trials.

Authors:  Daryl J Hoban; Jos Nauta
Journal:  Drug Des Devel Ther       Date:  2019-10-16       Impact factor: 4.162

5.  In Vitro Activity of the Novel Tetracyclines, Tigecycline, Eravacycline, and Omadacycline, Against Moraxella catarrhalis.

Authors:  Xiang Sun; Bo Zhang; Guangjian Xu; Junwen Chen; Yongpeng Shang; Zhiwei Lin; Zhijian Yu; Jinxin Zheng; Bing Bai
Journal:  Ann Lab Med       Date:  2021-05-01       Impact factor: 3.464

6.  Etiology and efficacy of anti-microbial treatment for community-acquired pneumonia in adults requiring hospital admission in Ukraine.

Authors:  Igor Kaidashev; Anna Lavrenko; Tatiana Baranovskaya; Victor Blazhko; Nataliia Digtiar; Oleksandr Dziublyk; Nataliia Gerasymenko; Liudmyla Iashyna; Volodymyr Kryvetskyi; Lesya Kuryk; Victoria Rodionova; Roman Stets; Ivan Vyshnyvetskyy; Yurii Feshchenko
Journal:  Acta Biomed       Date:  2022-05-11

7.  Molecular Epidemiology and Antimicrobial Resistance of Haemophilus influenzae in Adult Patients in Shanghai, China.

Authors:  Xin-Xin Li; Shu-Zhen Xiao; Fei-Fei Gu; Wei-Ping He; Yu-Xing Ni; Li-Zhong Han
Journal:  Front Public Health       Date:  2020-03-27

8.  Detection of Eight Respiratory Bacterial Pathogens Based on Multiplex Real-Time PCR with Fluorescence Melting Curve Analysis.

Authors:  Liuyang Hu; Bing Han; Qin Tong; Hui Xiao; Donglin Cao
Journal:  Can J Infect Dis Med Microbiol       Date:  2020-02-26       Impact factor: 2.471

9.  Effect of prior receipt of antibiotics on the pathogen distribution: a retrospective observational cohort study on 27,792 patients.

Authors:  Leiqing Li; Lingcheng Xu; Rongsheng Zhu; Jiaojiao Song; Xuanding Wang
Journal:  BMC Infect Dis       Date:  2020-01-06       Impact factor: 3.090

10.  Prevalences and characteristics of cultivable nasal bacteria isolated from preclinical medical students.

Authors:  Ke Zhou; Fei Sun; Xiu-Li Xu; Xiao-Ke Hao; Jia-Yun Liu
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.